The Benefits of Adjuvant Trastuzumab for HER‐2‐Positive Salivary Gland Cancers

BACKGROUND: Although high‐grade salivary gland cancers (SGCs) often express androgen receptor (AR) and/or HER‐2/neu, therapeutically targeting these receptors in SGC remains investigational. We investigated the prevalence of receptor expression and the benefit of adjuvant HER‐2 directed therapy in t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Hanna, Glenn J., Bae, Ji Eun, Lorch, Jochen H., Haddad, Robert I., Jo, Vickie Y., Schoenfeld, Jonathan D., Margalit, Danielle N., Tishler, Roy B., Goguen, Laura A., Annino, Donald J., Chau, Nicole G.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Head and Neck Cancers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7356716/
https://ncbi.nlm.nih.gov/pubmed/32310325
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0841
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados